CIK 0001720893 · Non-accelerated filer<br>Smaller reporting company
BioXcel Therapeutics, Inc.
Sign in to watch- Ticker
- BTAIQ
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 821386754
- Phone
- 203-643-8060
- Business address
- 555 LONG WHARF DRIVE, NEW HAVEN, CT, 06511
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 33 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-14 | Steinhart Richard I Chief Financial Officer | Option exercise · Restricted Stock Units 10b5-1 | −521 | 2,606 | ||
| 2024-12-14 | Rodriguez Javier See Remarks | Option exercise 10b5-1 | +521 | 24,291 | ||
| 2024-12-14 | Rodriguez Javier See Remarks | Option exercise · Restricted Stock Units 10b5-1 | −521 | 2,606 | ||
| 2024-12-14 | Yocca Frank Chief Scientific Officer | Option exercise 10b5-1 | +521 | 28,799 | ||
| 2024-12-14 | Yocca Frank Chief Scientific Officer | Option exercise · Restricted Stock Units 10b5-1 | −521 | 2,606 | ||
| 2024-11-30 | MACK DAVID J. Director | Option exercise 10b5-1 | +27,089 | 27,089 | ||
| 2024-11-30 | MACK DAVID J. Director | Option exercise · Restricted Stock Units 10b5-1 | −27,089 | 297,988 | ||
| 2024-11-30 | MACK DAVID J. Director | Option exercise 10b5-1 | +27,089 | 27,089 | ||
| 2024-11-21 | MACK DAVID J. Director | Grant or award · Restricted Stock Units 10b5-1 | +297,988 | 297,998 | ||
| 2024-11-21 | MACK DAVID J. Director | Grant or award · Restricted Stock Units | +325,077 | 325,077 | ||
| 2024-10-03 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 | −6,272 | $0.55 | $3K | 19,011 |
| 2024-10-03 | Rodriguez Javier See Remarks | Sale 10b5-1 | −6,863 | $0.55 | $4K | 23,770 |
| 2024-10-03 | Yocca Frank Chief Scientific Officer | Sale 10b5-1 | −7,175 | $0.55 | $4K | 28,278 |
| 2024-10-03 | Steinhart Richard I Chief Financial Officer | Sale 10b5-1 | −7,175 | $0.55 | $4K | 20,279 |
| 2024-10-03 | O'Neill Vincent See Remarks | Sale 10b5-1 | −5,556 | $0.55 | $3K | 19,601 |
| 2024-09-17 | Wiley Matthew T. Chief Commercial Officer | Grant or award 10b5-1 | +21,250 | 25,283 | ||
| 2024-09-17 | Rodriguez Javier See Remarks | Grant or award 10b5-1 | +21,250 | 30,633 | ||
| 2024-09-17 | Yocca Frank Chief Scientific Officer | Grant or award 10b5-1 | +21,250 | 35,453 | ||
| 2024-09-17 | Steinhart Richard I Chief Financial Officer | Grant or award 10b5-1 | +21,250 | 27,454 | ||
| 2024-09-17 | O'Neill Vincent See Remarks | Grant or award 10b5-1 | +21,250 | 25,157 |
Page 10 of 27 · 521 trades